SAN CARLOS, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on August 17, 2023 (the “Date of Grant”), the Company approved the grant…Read More
Iovance Biotherapeutics Inc Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635c4
